A carregar...
Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report
RATIONALE: Nivolumab (Nivo) is an immune checkpoint inhibitor that has been used to treat advanced melanoma, nonsmall cell lung carcinoma, and renal cell carcinoma since 2015. Nivo is associated with several side effects, including hepatitis, pneumonitis, acute renal failure, endocrine disorder, and...
Na minha lista:
| Publicado no: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer Health
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5502156/ https://ncbi.nlm.nih.gov/pubmed/28682883 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000007350 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|